With A Return On Equity Of 20%, Has Medexus Pharmaceuticals Inc.'s (TSE:MDP) Management Done Well?

Yahoo FinanceMay 8 10:16

Medexus Concludes Metoject Litigation, Patent No Longer in Effect in Canada

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - May 1, 2024) - Following a trial in January 2023, Canada's Federal Court has issued a judgment declining to uphold the Canadian patent for Met

newsfileMay 1 16:30

Medexus to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - April 2, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that company management will be participating in the

newsfileApr 2 06:30

FDA Approves Medexus's Supplemental Biologics License Application for IXINITY(R) to Treat Hemophilia B in Pediatric Patients

Expanded indication includes patients under 12 years of age, based on Phase 3/4 data demonstrating safety and efficacy in previously treated patients in this age groupToronto, Ontario and Chicago, Ill

newsfileMar 26 06:53

Medexus Pharmaceuticals Inc Price Target Cut to C$2.35/Share From C$2.85 by Stifel Nicolaus

Medexus Pharmaceuticals Inc Price Target Cut to C$2.35/Share From C$2.85 by Stifel Nicolaus

Dow JonesFeb 22 10:33

Medexus Pharmaceuticals Inc. Just Reported A Surprise Loss: Here's What Analysts Think Will Happen Next

Yahoo FinanceFeb 10 06:24